Atripla™ (efavirenz 600 mg, emtricitabine 200 mg, and tenofovir disoproxil fumarate 300 mg)

Source :: Clinician Reviews. November, 2006, Vol. 16 Issue 11, p55, 1 p.
Publication Year :: 2006
Abstract: Bristol-Myers Squibb Company and Gilead Sciences, Inc Atripla combines two already-approved products--Bristol-Myers Squibb's Sustiva® and Gilead Science's Truvada®--in the first once-daily, single-dose regimen for the treatment of HW-1 in adults. [...]

Subjects :: Bristol-Myers Squibb Co. -- Research agreements -- Product introduction
Gilead Sciences Inc. -- Research agreements -- Product introduction
Biological products industry -- Research agreements -- Product introduction
Antiviral agents -- Product introduction
Anti-HIV agents -- Product introduction
Pharmaceutical industry -- Research agreements -- Product introduction
Health
Atripla (Medication) -- Product introduction

Tools